![]() |
市場調查報告書
商品編碼
2088717
細胞計數市場:2026-2032年全球市場預測(依產品類型、技術、細胞類型、應用、最終用戶和組織規模分類)Cell Counting Market by Product Type, Technology, Cell Type, Application, End User, Organization Size - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,細胞計數市場將成長至 149 億美元,複合年成長率為 8.45%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 84.4億美元 |
| 預計年份:2026年 | 91.1億美元 |
| 預測年份:2032年 | 149億美元 |
| 複合年成長率 (%) | 8.45% |
細胞數是一項基礎技術,廣泛應用於生命科學、臨床診斷、生物製程、免疫學、腫瘤學、細胞治療、微生物學和藥物研發等領域。隨著生物製藥、疫苗研發、再生醫學的蓬勃發展,以及常規血液學工作流程的廣泛應用(這些流程都需要精確測量細胞濃度、活力和表現型),細胞計數的需求正在不斷成長。
市場正從手動血球計數器轉向自動化細胞計數器、流式細胞技術、影像分析、耗材和軟體平台。公共衛生和研究領域的成熟指標支持這一轉變。根據國際癌症研究機構 (IARC) 預測,2022 年全球將新患者,而美國國立衛生研究院 (NIH)、歐盟和各國研究經費將繼續支持細胞研究、免疫療法和轉化醫學。這些趨勢使得細胞計數成為實現可重複研究、可靠診斷和符合監管要求的關鍵要素。
細胞計數領域正透過整合自動化、小型化、成像、螢光和分析技術而改變。實驗室正在採用自動化系統取代耗時的手動方法,從而減少操作人員的差異,提高處理能力,並在品管的環境下加強記錄保存。
人工智慧 (AI) 透過改進影像分割、碎片去除、細胞形態分類、活力評估和異常檢測,對細胞計數整體產生了累積的影響。 AI 驅動的影像分析有助於減少明場和螢光分析工作流程中的主觀性,尤其是當細胞聚集、低對比度或異質性樣本等情況會降低傳統閾值計數可靠性時。
北美憑藉其成熟的生物技術產業叢集、強大的臨床研究基礎設施以及自動化血液學檢測、流式細胞技術和生物製程分析的高普及率,持續引領細胞計數技術的應用。美國透過生物製藥生產、癌症研究和細胞療法開發來滿足市場需求,而加拿大則透過學術研究網路、醫院檢查室和公共衛生計畫做出貢獻。
隨著新加坡、馬來西亞、泰國、印尼、越南和菲律賓不斷加強生物醫學研究、醫院網路和區域製造體系,東協的重要性日益凸顯。臨床檢查室的擴張以及公共和私人醫療保健投資的增加推動了這一需求,而新加坡作為尖端研究、轉化醫學和品管系統的高價值中心,發揮關鍵作用。
美國正透過生物製藥研發、由美國國立衛生研究院(NIH)支持的生物醫學研究、由美國食品藥物管理局(FDA)監管的細胞療法活動以及豐富的臨床和實驗室應用經驗,推動全球需求成長。在加拿大,相關技術在大學醫院、癌症中心、公共研究機構和傳染病檢查實驗室的應用也正在穩步推進。同時,墨西哥則透過診斷技術的現代化、醫院的擴建以及製藥生產的整合,實現了成長。
行業領導者應優先考慮能夠提高可重複性、減少人工操作並與實驗室資訊管理系統和電子批次記錄整合的自動化平台。產品系列應配備經過檢驗的方案、應用說明、校準支援和培訓計劃,以滿足高性能生物製程和注重成本效益的臨床檢查室的需求。
本調查方法採用系統性的方法,結合了二手資料研究、一手檢驗和分析三角測量。二手資料包括監管資料庫、臨床實驗室註冊資訊、同行評審的紙本文件、產品文件、公共衛生資料集以及世界衛生組織、國際癌症研究機構、美國食品藥物管理局、歐洲藥品管理局、美國國立衛生研究院、經濟合作暨發展組織和國家統計機構等權威機構的資訊。
隨著生命科學研究、臨床診斷和細胞生產在全球範圍內的擴張,細胞計數市場正變得日益自動化、數據驅動,並具有重要的戰略意義。推動這一成長的因素包括癌症負擔的加重、生物製藥研發管線的擴展、對先進療法和疫苗生產的投資,以及對可重複且受監管的實驗室工作流程的需求。
The Cell Counting Market is projected to grow by USD 14.90 billion at a CAGR of 8.45% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 8.44 billion |
| Estimated Year [2026] | USD 9.11 billion |
| Forecast Year [2032] | USD 14.90 billion |
| CAGR (%) | 8.45% |
Cell counting is a foundational capability across life sciences, clinical diagnostics, bioprocessing, immunology, oncology, cell therapy, microbiology, and drug discovery. Demand is being reinforced by the expansion of biologics, vaccine development, regenerative medicine, and routine hematology workflows that require accurate cell concentration, viability, and phenotype measurement.
The market is moving beyond manual hemocytometers toward automated cell counters, flow cytometry, image-based analysis, consumables, and software-enabled platforms. Verified public health and research indicators support this shift: the International Agency for Research on Cancer reported about 20 million new cancer cases globally in 2022, while sustained NIH, EU, and national research funding continues to support cellular research, immunotherapy, and translational medicine. These trends make cell counting a critical enabler of reproducible research, diagnostic reliability, and regulated manufacturing.
The cell counting landscape is being reshaped by automation, miniaturization, and the convergence of imaging, fluorescence, and analytics. Laboratories are replacing time-intensive manual methods with automated systems that reduce operator variability, accelerate throughput, and improve documentation for quality-controlled environments.
A second major shift is the rise of cell and gene therapy manufacturing, where viable cell counts and process consistency are essential for batch release, potency testing, and regulatory compliance. At the same time, decentralized diagnostics, academic core facilities, and contract research organizations are adopting connected instruments to standardize workflows across multi-site operations. These shifts are increasing the importance of validated consumables, calibration routines, electronic records, and workflow-compatible software.
Artificial intelligence is creating a cumulative impact across cell counting by improving image segmentation, debris exclusion, cell morphology classification, viability assessment, and anomaly detection. AI-enabled image analysis can help reduce subjectivity in brightfield and fluorescence workflows, particularly where cell clumping, low contrast, or heterogeneous samples make traditional threshold-based counting less reliable.
In regulated bioprocessing and clinical research, AI is also strengthening data integrity through automated audit trails, predictive maintenance signals, and workflow standardization. The highest-value use cases are emerging where AI complements validated laboratory methods rather than replacing scientific oversight, supporting faster decisions while preserving traceability, quality control, and compliance.
North America remains a leading region for cell counting adoption due to mature biotechnology clusters, strong clinical research infrastructure, and high use of automated hematology, flow cytometry, and bioprocess analytics. The United States anchors demand through biopharma manufacturing, cancer research, and cell therapy development, while Canada contributes through academic research networks, hospital laboratories, and public health programs.
Asia-Pacific is expanding as China, India, Japan, South Korea, Australia, and ASEAN economies invest in biomanufacturing, diagnostics, pharmaceutical R&D, and clinical laboratory capacity. Europe benefits from strong life science regulation, research funding, advanced therapy activity, and established diagnostic systems across the European Union and the United Kingdom. Latin America is advancing through hospital modernization, infectious disease surveillance, and research partnerships, led by Brazil and Mexico. The Middle East is investing in precision medicine, oncology care, and healthcare infrastructure, particularly across GCC countries, while Africa shows rising demand for scalable diagnostics, infectious disease monitoring, hematology testing, and laboratory capacity building.
ASEAN is gaining relevance as Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines strengthen biomedical research, hospital networks, and regional manufacturing. Demand is supported by expanding clinical laboratories and public-private healthcare investment, with Singapore acting as a high-value hub for advanced research, translational medicine, and quality systems.
The GCC is prioritizing precision medicine, oncology care, and health system modernization, creating opportunities for automated and connected cell counting solutions. The European Union emphasizes regulatory harmonization, quality assurance, advanced therapy development, and cross-border research collaboration. BRICS countries contribute scale through large patient populations, expanding domestic biopharma capacity, vaccine manufacturing, and public research initiatives. G7 markets lead in premium instruments, clinical adoption, bioprocess innovation, and data governance, while NATO economies benefit from resilient supply chain planning, biodefense research, and standardized laboratory infrastructure.
The United States leads global demand through biopharmaceutical R&D, NIH-supported biomedical research, FDA-regulated cell therapy activity, and a large installed base of clinical and research laboratories. Canada shows steady uptake in academic hospitals, cancer centers, public research institutions, and infectious disease laboratories, while Mexico is growing through diagnostics modernization, hospital expansion, and pharmaceutical manufacturing integration.
Brazil is Latin America's strongest opportunity due to its hospital network, public health research, clinical laboratory base, and pharmaceutical sector. In Europe, the United Kingdom, Germany, France, Italy, and Spain support advanced diagnostics, life science research, cancer care, and bioprocessing, while Russia maintains demand in state-backed research institutes and clinical laboratories. China is scaling cell counting through biomanufacturing, oncology research, and hospital diagnostics; India is driven by diagnostics volume, vaccine production, biosimilars, and expanding private laboratory networks; Japan emphasizes precision instrumentation, regenerative medicine, and quality-focused clinical workflows; Australia supports translational research, clinical trials, and public health laboratories; and South Korea combines biopharma investment with advanced hospital infrastructure and strong adoption of automated laboratory technologies.
Industry leaders should prioritize automation platforms that improve reproducibility, reduce manual handling, and integrate with laboratory information management systems and electronic batch records. Product portfolios should address both high-throughput bioprocessing and cost-sensitive clinical laboratories, supported by validated protocols, application notes, calibration support, and training programs.
Vendors should strengthen AI-enabled image analysis while maintaining transparent validation, auditability, cybersecurity, and compliance alignment. Strategic growth will come from partnerships with cell therapy manufacturers, contract development and manufacturing organizations, academic core labs, diagnostics networks, and public health laboratories. Regional strategies should combine premium systems for mature markets with modular, serviceable, and consumable-efficient platforms for emerging economies.
The research methodology applies a structured approach combining secondary research, primary validation, and analytical triangulation. Secondary sources include regulatory databases, clinical trial registries, peer-reviewed publications, product documentation, public health datasets, and recognized institutions such as WHO, IARC, FDA, EMA, NIH, OECD, and national statistical agencies.
Primary inputs are validated through interviews and market discussions with laboratory managers, bioprocessing specialists, diagnostics stakeholders, distributors, and industry executives. Findings are cross-checked across demand indicators, technology adoption patterns, installed-base behavior, procurement cycles, regulatory requirements, reimbursement context, and regional policy developments to ensure accuracy, relevance, and decision-ready insight.
The cell counting market is becoming more automated, data-driven, and strategically important as life science research, clinical diagnostics, and cell-based manufacturing scale worldwide. Growth is supported by rising cancer burden, expanding biologics pipelines, investment in advanced therapies, vaccine production, and the need for reproducible, compliant laboratory workflows.
Organizations that combine reliable instrumentation, validated consumables, AI-assisted analytics, and strong service coverage will be best positioned to capture demand. The next phase of competition will favor platforms that deliver accuracy, workflow efficiency, regulatory confidence, data integrity, and seamless integration across research, clinical, and manufacturing environments.